Loading…
KALA BIO, Inc. is projected to decline to $0.7052 by 2027, a -10% move from its current price of $0.783. KALA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.7261 | $0.7823 | $0.8428 | -0.10% |
| Aug 6 | $0.7033 | $0.7815 | $0.8684 | -0.19% |
| Aug 7 | $0.6862 | $0.7808 | $0.8884 | -0.28% |
| Aug 8 | $0.672 | $0.78 | $0.9054 | -0.38% |
| Aug 9 | $0.6596 | $0.7793 | $0.9206 | -0.47% |
| Aug 10 | $0.6486 | $0.7785 | $0.9345 | -0.57% |
| Aug 11 | $0.6386 | $0.7778 | $0.9474 | -0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6386 | $0.7778 | $0.9474 | -0.66% |
| Week 2 | $0.5846 | $0.7726 | $1.02 | -1.32% |
| Week 3 | $0.5454 | $0.7675 | $1.08 | -1.98% |
| Week 4 | $0.5139 | $0.7624 | $1.13 | -2.63% |
| Week 5 | $0.4873 | $0.7574 | $1.18 | -3.27% |
| Week 6 | $0.4641 | $0.7524 | $1.22 | -3.91% |
| Week 7 | $0.4435 | $0.7474 | $1.26 | -4.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
KALA BIO, Inc. is a biopharmaceutical company that engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. It serves biotechnology and pharmaceutical companies. It was formerly known as Kala Pharmaceuticals, Inc.
and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. trades at $0.7297 and has a market capitalization of $13.56M. It is ranked 4726 by market cap. The stock sits in the Healthcare sector and is positioned among small-cap biotechnology names. The current price and market positioning provide a baseline for evaluating the outlook from the 2026–2050 forecast series.
The near-term forecast for 2026 shows a min of $0.61, an average of $0.7297, and a max of $0.9495, implying limited movement around the current level. The 30-day price range and volatility backdrop suggest a cautious stance in the shorter term.
Longer-term projections illustrate potential upside across years, with 2029 showing an avg of $0.905 and 2030 at $0.9866, rising toward the later years where the max prices expand to the vicinity of $6.01 by 2050. See also 2050’s max forecast of $6.01 and an overall implied growth path to multi-year highs, with corresponding ROI figures including 35.2% in 2030 and 258.2% in 2050.
A major floor 22.1% below — a decisive break under it would weaken the trend.
The nearest floor, 22.1% below — buyers have tended to step in here.
The nearest ceiling, 361.0% above — a clean break opens room to run.
A major ceiling 1343.2% above — clearing it would confirm fresh momentum.
Key KALA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KALA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.698 | Buy | $0.7159 | Buy |
| MA 10 | $0.6954 | Buy | $0.7667 | Buy |
| MA 20 | $0.9312 | Sell | $1.04 | Sell |
| MA 50 | $1.86 | Sell | $2.60 | Sell |
| MA 100 | $5.16 | Sell | $13.49 | Sell |
| MA 200 | $18.98 | Sell | $59.89 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.39 | Buy |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -44.97 | Neutral |
| Williams %R (14) | -65.24 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | -26.60 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 34.76 | Neutral |
| TRIX (15) | -3.81 | Sell |
| Awesome (5,34) | -0.93 | Sell |
| Ultimate (7,14,28) | 39.85 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 0.72 | Buy |
| ADX (14) | 45.03 | Sell |
| ATR (14) | 0.10 | Info |
The sentiment score is NEUTRAL, and the RSI(14) is 30, indicating potential oversold pressure but no clear directional bias. The 50-day simple moving average stands at $1.89, while the 200-day simple moving average sits at $19.35, showing a wide gap that can reflect limited liquidity and volatility in this small-cap name. Support is identified at $0.61 and resistance at $3.61, framing a broad trading range.
The thirty-day price range spans from $0.4412 to $1.21, highlighting a recent short-term swing that keeps the price within a relatively tight corridor around the current level. Traders may watch for a bounce toward the near-term resistance or a decline toward the established support as catalysts unfold.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.61 | $0.783 | $1.03 | 0% | Neutral | |
| $0.5139 | $0.7052 | $1.05 | -10% | Neutral | |
| $0.46 | $0.6714 | $1.06 | -14% | Neutral | |
| $0.6333 | $0.9741 | $1.62 | +24% | Bullish | |
| $0.6551 | $1.06 | $1.83 | +35% | Bullish | |
| $0.5943 | $1.00 | $1.80 | +28% | Bullish | |
| $0.5673 | $0.9977 | $1.84 | +27% | Bullish | |
| $0.4306 | $0.7888 | $1.50 | +1% | Neutral | |
| $0.4557 | $0.8683 | $1.69 | +11% | Neutral | |
| $0.5629 | $1.11 | $2.22 | +42% | Bullish | |
| $0.5443 | $1.21 | $2.65 | +54% | Bullish | |
| $1.27 | $2.82 | $6.49 | +260% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.61 | $0.783 | $0.9869 | +0.00% |
| September 2026 | $0.6189 | $0.7523 | $0.9541 | -3.92% |
| October 2026 | $0.5825 | $0.718 | $0.9291 | -4.57% |
| November 2026 | $0.6097 | $0.7601 | $0.9996 | +5.86% |
| December 2026 | $0.61 | $0.7684 | $1.03 | +1.10% |
Click any year to see its month-by-month KALA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, KALA could reach as high as $1.03, with a base case around $0.783 and support toward $0.61 — roughly 0% from $0.783. Price action looks broadly range-bound.
Expect KALA to range from $0.5139 to $1.05 through 2027. The $0.7052 average target implies a -10% move from current prices. That is -10% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The KALA price prediction for 2028 points to an average of $0.6714 (low $0.46, high $1.06) — a potential decline of -14% on today's $0.783. Price action looks broadly range-bound.
In 2029, KALA is projected to trade between $0.6333 and $1.62, averaging $0.9741 — a potential gain of +24% from today's $0.783. That is up +45% on the projected 2028 average. Buyers look set to stay in control over this stretch.
KALA BIO, Inc.'s 2030 outlook centres on $1.06, within a $0.6551 to $1.83 range. That is up +8% on the projected 2029 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2031, KALA could reach as high as $1.80, with a base case around $1.00 and support toward $0.5943 — roughly +28% from $0.783. Buyers look set to stay in control over this stretch.
Expect KALA to range from $0.5673 to $1.84 through 2032. The $0.9977 average target implies a +27% move from current prices. That is 0% versus the projected 2031 average. Momentum favours further upside here.
The KALA price prediction for 2033 points to an average of $0.7888 (low $0.4306, high $1.50) — a potential gain of +1% on today's $0.783. A consolidation phase looks the most probable path here.
In 2034, KALA is projected to trade between $0.4557 and $1.69, averaging $0.8683 — a potential gain of +11% from today's $0.783. That is up +10% on the projected 2033 average. Price action looks broadly range-bound.
KALA BIO, Inc.'s 2035 outlook centres on $1.11, within a $0.5629 to $2.22 range. That is up +28% on the projected 2034 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, KALA could reach as high as $2.65, with a base case around $1.21 and support toward $0.5443 — roughly +54% from $0.783. Momentum favours further upside here.
Expect KALA to range from $1.27 to $6.49 through 2050. The $2.82 average target implies a +260% move from current prices. That is up +133% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in KALA today (≈ 1,277.139208 KALA) could be worth
$3,604.31
+$2,604.31 (+260%) by 2050 · US Dollar
Based on the average projected KALA price of $2.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KALAwould be worth at today's price.
$1,000 invested in KALA on Jul 31, 2025 (≈ 2.95421 KALA) would be worth
$2.31
-$997.69 (-99.8%) today · 0.00× · US Dollar
Based on a KALA entry price of $338.5 vs. today's $0.783.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.634 | $1,235.02 | +23.5% |
| 1 month ago | $1.78 | $439.89 | -56.0% |
| 3 months ago | $5.45 | $143.67 | -85.6% |
| 6 months ago | $26.4 | $29.66 | -97.0% |
| 1 year ago | $338.5 | $2.31 | -99.8% |
| All time (5.0y) ago | $7,950 | $0.1 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KALA forecast.
Our base-case forecast reaches $1.60 around 2050.
Implied market cap at $1.60: $29.74M
The multi-year forecast shows a pathway from steady near-term performance to substantial longer-term upside. In 2029 the avg is $0.905 with a 24% ROI, and in 2030 the avg rises to $0.9866 with a 35.2% ROI, signaling a meaningful lift in value over the decade. The 2031 and 2032 forecasts continue to reflect bullish momentum, with ROIs of 28.5% and 26.2% respectively.
By 2035, the avg price is $1.03 with a max of $2.06 and a 41.7% ROI, followed by a 2040 forecast of avg $1.13, max $2.49, and a 55.4% ROI. The long-run expectation culminates in 2050, where the avg is $2.61, the max is $6.01, and the ROI reaches 258.2%. While these figures point to substantial upside, they coexist with years of more modest or even negative momentum in the 2027–2028 interval, underscoring the inherent uncertainty and volatility of a small-cap biotech equity.
Overall, the outlook is bullish over the multi-year horizon, but investors should balance the upside against the risk of drawdowns in certain periods. These are estimates and not guarantees, and actual results will vary with market conditions and company developments.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $0.6114, an avg of $0.9866, and a max of $1.71, with a projected ROI of 35.2% and a bullish sentiment.
Forecasts show a mix of years with negative ROI (e.g., 2027: -10.4%, 2028: -13.2%) and years with substantial upside (2050: ROI 258.2%, max $6.01). The 2029–2035 period includes bullish years (e.g., 2029 avg $0.905, ROI 24%; 2030 avg $0.9866, ROI 35.2%). These are estimates and not guarantees.
Yes, the forecast includes prices at or above $2.00 in multiple years: 2035 max $2.06, 2040 max $2.49, and 2050 max $6.01.
The thirty-day range is $0.4412 to $1.21, indicating recent volatility within that band.
Current price is $0.7297 and market cap is $13.56M. The asset is ranked 4726 by market capitalization.
KALA BIO, Inc. Community Discussion
0Share your KALA BIO, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.